Nothing Special   »   [go: up one dir, main page]

JO3281B1 - مركبات بينزوفوران لمعالجة عدوى فيروس إلتهاب الكبد الوبائي - Google Patents

مركبات بينزوفوران لمعالجة عدوى فيروس إلتهاب الكبد الوبائي

Info

Publication number
JO3281B1
JO3281B1 JOP/2012/0233A JOP20120233A JO3281B1 JO 3281 B1 JO3281 B1 JO 3281B1 JO P20120233 A JOP20120233 A JO P20120233A JO 3281 B1 JO3281 B1 JO 3281B1
Authority
JO
Jordan
Prior art keywords
hepatitis
treatment
virus infections
compounds
benzofuran compounds
Prior art date
Application number
JOP/2012/0233A
Other languages
English (en)
Inventor
James Peat Andrew
Yoke Chong Pek
F Miller John
Brad Shotwell John
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47746761&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3281(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of JO3281B1 publication Critical patent/JO3281B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

يتعلق الاختراع الحالي بمركبات من الصيغة (I): وأملاح منه، وتركيبات صيدلانية تتضمن المركبات المذكورة، واستخدامات هذه المركبات في العلاج أو الوقاية من حالات الإصابة بعدوى فيروسية، مثل حالات الإصابة بعدوى فيروس HCV، والأمراض المصاحبة لمثل هذه الإصابات.
JOP/2012/0233A 2011-08-19 2012-08-16 مركبات بينزوفوران لمعالجة عدوى فيروس إلتهاب الكبد الوبائي JO3281B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161525440P 2011-08-19 2011-08-19
US201261650681P 2012-05-23 2012-05-23

Publications (1)

Publication Number Publication Date
JO3281B1 true JO3281B1 (ar) 2018-09-16

Family

ID=47746761

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2012/0233A JO3281B1 (ar) 2011-08-19 2012-08-16 مركبات بينزوفوران لمعالجة عدوى فيروس إلتهاب الكبد الوبائي

Country Status (37)

Country Link
US (2) US8927593B2 (ar)
EP (2) EP3199531A1 (ar)
JP (2) JP6367712B2 (ar)
KR (1) KR101913800B1 (ar)
CN (1) CN103732065B (ar)
AR (1) AR087563A1 (ar)
AU (1) AU2012299295B2 (ar)
BR (1) BR112014002845A2 (ar)
CA (1) CA2844086A1 (ar)
CL (2) CL2014000393A1 (ar)
CO (1) CO6862153A2 (ar)
CR (1) CR20140078A (ar)
CY (1) CY1118399T1 (ar)
DK (1) DK2744332T3 (ar)
DO (1) DOP2014000034A (ar)
EA (1) EA032841B1 (ar)
ES (1) ES2611731T3 (ar)
HR (1) HRP20161743T1 (ar)
HU (1) HUE030300T2 (ar)
IL (1) IL230487B (ar)
IN (1) IN2014CN00572A (ar)
JO (1) JO3281B1 (ar)
LT (1) LT2744332T (ar)
MA (1) MA35443B1 (ar)
ME (1) ME02588B (ar)
MX (1) MX354676B (ar)
PE (1) PE20141201A1 (ar)
PL (1) PL2744332T3 (ar)
PT (1) PT2744332T (ar)
RS (1) RS55462B1 (ar)
SG (1) SG10201606883QA (ar)
SI (1) SI2744332T1 (ar)
SM (1) SMT201700028B (ar)
TW (1) TWI538915B (ar)
UY (1) UY34274A (ar)
WO (1) WO2013028371A1 (ar)
ZA (1) ZA201401020B (ar)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9119868B2 (en) * 2011-08-17 2015-09-01 Glaxosmithkline Llc Therapeutic methods
EP3199531A1 (en) 2011-08-19 2017-08-02 Glaxo Group Limited Benzofuran compounds for the treatment of hepatitis c virus infections
MA40805A (fr) 2014-11-10 2017-09-20 Glaxosmithkline Ip No 2 Ltd Compositions pharmaceutiques à action prolongée contre l'hépatite c
AU2015344741A1 (en) * 2014-11-10 2017-05-25 Glaxosmithkline Intellectual Property (No.2) Limited Combination long acting compositions and methods for hepatitis C
KR20180006522A (ko) 2016-07-07 2018-01-18 삼성디스플레이 주식회사 액정 조성물 및 이를 포함하는 액정 표시 장치
US11738088B2 (en) 2016-08-01 2023-08-29 University of Pittsburgh—of the Commonwealth System of Higher Education Boryl ethers, carbonates, and cyclic acetals as oxidatively-triggered drug delivery vehicles
MX2019010404A (es) * 2017-03-02 2019-11-21 Assembly Biosciences Inc Compuestos sulfamida cíclicos y métodos de uso de los mismos.
US11649238B2 (en) * 2018-01-17 2023-05-16 Glaxosmithkline Intellectual Property Development Limited Substituted pyrazolo[1,5-a]pyrimidines as PI4K inhibitors
CA3155559A1 (en) * 2019-10-25 2021-04-29 Sachiko Koike Novel substituted condensed ring compound
CN111026203B (zh) * 2019-12-02 2021-01-26 宁波德晶元科技有限公司 一种适用于真空热水壶的加热控制方法与系统

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
WO2001002424A2 (en) * 1999-07-07 2001-01-11 Du Pont Pharmaceuticals Company Peptide boronic acid inhibitors of hepatitis c virus protease
EP2251344B2 (en) 2001-01-25 2024-04-24 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Formulation of boronic acid compounds
EP1581207A4 (en) * 2002-11-01 2007-07-25 Viropharma Inc BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING AND PROPHYLAXIS OF VIRAL INFECTIONS WITH HEPATITIS C AND RELATED ILLNESSES
AU2006349612A1 (en) * 2005-12-01 2008-05-02 Wyeth Anthranilic acid derivatives useful in treating infection with Hepatitis C virus
KR20130120552A (ko) 2006-02-16 2013-11-04 아나코르 파마슈티칼스 인코포레이티드 항염증제로서 보론함유 소분자
BRPI0711155A2 (pt) * 2006-05-02 2011-08-23 Anacor Pharmaceuticals Inc terapêuticos contendo boro resistentes hidroliticamente e métodos de uso
US20070286822A1 (en) 2006-06-12 2007-12-13 Anacor Pharmaceuticals Inc. Compounds for the Treatment of Periodontal Disease
US7858666B2 (en) 2007-06-08 2010-12-28 Mannkind Corporation IRE-1α inhibitors
GB0719366D0 (en) * 2007-10-03 2007-11-14 Smithkline Beecham Corp Compounds
CA2714254A1 (en) * 2008-02-14 2009-08-20 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
EP2187893A4 (en) 2008-03-06 2012-02-22 Anacor Pharmaceuticals Inc SMALL BORON-CONTAINING MOLECULES AS ANTI-INFLAMMATORY AGENTS
WO2009137500A1 (en) 2008-05-05 2009-11-12 Wyeth 6-substituted benzofuran compounds to treat infection with hepatitis c virus
WO2009137493A1 (en) 2008-05-05 2009-11-12 Wyeth 2-substituted benzofuran compounds to treat infection with hepatitis c virus
US7737157B2 (en) 2008-08-29 2010-06-15 Hutchison Medipharma Enterprises Limited Pyrimidine compounds
EP2348863A4 (en) 2008-09-04 2012-03-07 Anacor Pharmaceuticals Inc BORN SMALL MOLECULES
WO2011050284A1 (en) * 2009-10-23 2011-04-28 Glaxosmithkline Llc Pyrazolylpyridine antiviral agents
AR080185A1 (es) 2010-02-19 2012-03-21 Glaxo Group Ltd Derivados de acido boronico y benzofurano, composiciones farmaceuticas que los contienen,y uso de los mismos en el tratamiento y/o prevencion de infecciones virales, en particular por el virus de hepatitis c(hcv).
WO2011106986A1 (en) 2010-03-02 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus ns5b polymerase
WO2011106929A1 (en) 2010-03-02 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus ns5b polymerase
TW201136919A (en) 2010-03-02 2011-11-01 Merck Sharp & Amp Dohme Corp Inhibitors of hepatitis C virus NS5B polymerase
AU2011329486A1 (en) 2010-11-18 2013-04-18 Glaxo Group Limited Compounds
AU2011329485A1 (en) 2010-11-18 2013-04-18 Glaxo Group Limited Compounds
US9119868B2 (en) * 2011-08-17 2015-09-01 Glaxosmithkline Llc Therapeutic methods
WO2013025975A1 (en) * 2011-08-17 2013-02-21 Glaxosmithkline Llc Combination treatments for hepatitis c
EP3199531A1 (en) 2011-08-19 2017-08-02 Glaxo Group Limited Benzofuran compounds for the treatment of hepatitis c virus infections

Also Published As

Publication number Publication date
US9682999B2 (en) 2017-06-20
UY34274A (es) 2013-04-05
RS55462B1 (sr) 2017-04-28
KR101913800B1 (ko) 2018-11-01
EP3199531A1 (en) 2017-08-02
US20150080343A1 (en) 2015-03-19
US20130237501A1 (en) 2013-09-12
SI2744332T1 (sl) 2017-01-31
BR112014002845A2 (pt) 2017-02-21
PT2744332T (pt) 2017-01-24
JP6367712B2 (ja) 2018-08-01
DOP2014000034A (es) 2014-06-01
CA2844086A1 (en) 2013-02-28
HUE030300T2 (en) 2017-04-28
CL2014000393A1 (es) 2014-08-01
ZA201401020B (en) 2020-11-25
KR20140054287A (ko) 2014-05-08
JP2017125010A (ja) 2017-07-20
PE20141201A1 (es) 2014-10-03
CO6862153A2 (es) 2014-02-10
IN2014CN00572A (ar) 2015-04-03
TW201321390A (zh) 2013-06-01
CN103732065A (zh) 2014-04-16
MX2014001989A (es) 2014-02-27
AU2012299295A1 (en) 2014-02-20
JP2014527529A (ja) 2014-10-16
EA032841B1 (ru) 2019-07-31
US8927593B2 (en) 2015-01-06
AU2012299295B2 (en) 2016-03-31
SMT201700028B (it) 2017-03-08
ME02588B (me) 2017-06-20
SG10201606883QA (en) 2016-10-28
TWI538915B (zh) 2016-06-21
CY1118399T1 (el) 2017-06-28
CL2017000293A1 (es) 2017-10-06
IL230487B (en) 2019-06-30
EP2744332B1 (en) 2016-10-26
DK2744332T3 (en) 2017-01-16
PL2744332T3 (pl) 2017-03-31
MA35443B1 (fr) 2014-09-01
CR20140078A (es) 2014-03-20
WO2013028371A1 (en) 2013-02-28
CN103732065B (zh) 2016-10-26
EP2744332A1 (en) 2014-06-25
MX354676B (es) 2018-03-15
AR087563A1 (es) 2014-04-03
IL230487A0 (en) 2014-03-31
EP2744332A4 (en) 2015-01-14
HRP20161743T1 (hr) 2017-02-24
EA201490213A1 (ru) 2014-07-30
LT2744332T (lt) 2017-01-10
ES2611731T3 (es) 2017-05-10

Similar Documents

Publication Publication Date Title
JO3281B1 (ar) مركبات بينزوفوران لمعالجة عدوى فيروس إلتهاب الكبد الوبائي
PH12014502739A1 (en) Macrocyclic inhibitors of flaviviridae viruses
NZ724503A (en) Macrocyclic inhibitors of flaviviridae viruses
MY170941A (en) Pyrimidine derivatives for the treatment of viral infections
EA201390538A1 (ru) Противовирусные соединения
NZ703066A (en) Macrocyclic inhibitors of flaviviridae viruses
MY182771A (en) Viral replication inhibitors
MX2012008221A (es) Inhibidores de virus flaviviridae.
MX2012008211A (es) Inhibidores de virus flaviviridae.
NZ703064A (en) Inhibitors of hepatitis c virus
MX2012000959A (es) Inhibidores de los virus flaviviridae.
PH12015502230B1 (en) Novel viral replication inhibitors
EA026667B9 (ru) Фармацевтическая композиция для лечения вируса гепатита с
MX2013006475A (es) Inhibidores macrociclicos de virus flaviviridae.
BR112013020042A2 (pt) inibidores de vírus da hepatite c
IN2012DN01855A (ar)
IN2014MN01548A (ar)
BR112013028679A2 (pt) inibidores do vírus da hepatite c
BR112014015582A8 (pt) compostos antivirais
MX2013004464A (es) Inhibidores de polimerasa viral.
PH12019501907A1 (en) Novel viral replication inhibitors
UA113048C2 (xx) Противірусні сполуки
TN2013000335A1 (en) Hepatitis c virus inhibitors